Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
We conducted a randomized controlled trial of adjuvant interferon (IFN) therapy in patients
with hepatitis-C virus (HCV)-related cirrhosis who underwent curative resection of
hepatocellular carcinoma (HCC) to investigate whether IFN could reduce or delay the incidence
of recurrent tumor (secondary/tertiary prevention of HCC). Patients were randomly assigned to
treatment with IFN (3MU thrice/wk /48 weeks) vs. no treatment after curative resection of
HCC(control group)